Business Context and Reporting Period
Company: The Coca-Cola Company (KO)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 28, 2025
Reporting Status: Large accelerated filer; 4,304,266,738 shares of common stock outstanding as of April 29, 2025.
The Company reported results for the first quarter of 2025, which included two fewer days than the comparable period in 2024. The reporting period reflects the sunsetting of the Global Ventures operating segment, with results for Costa, innocent, and doTadaan now reported within the Europe, Middle East, and Africa segment.
Key Financial Metrics
| Metric (in millions, except per share) | Q1 2025 | Q1 2024 |
|---|---|---|
| Net Operating Revenues | $11,129 | $11,300 |
| Gross Profit | $6,966 | $7,065 |
| Operating Income | $3,659 | $2,141 |
| Net Income Attributable to Shareowners | $3,330 | $3,177 |
| Diluted Earnings Per Share | $0.77 | $0.74 |
| Operating Cash Flow | ($5,202) Used | $528 Provided |
| Cash and Cash Equivalents | $8,417 | $10,443 |
| Total Debt (Current + Long-term) | $49,111 | $43,522 (Dec 31, 2024) |
Margins: Gross profit margin increased to 62.6% (from 62.5% in Q1 2024). Operating margin improved significantly to 32.9% (from 18.9% in Q1 2024).
Material Changes vs. Prior Period
- Revenue: Decreased 2% to $11.1 billion, driven by a 5% unfavorable impact from foreign currency fluctuations and a 3% impact from acquisitions and divestitures, partially offset by a 5% favorable price, product, and geographic mix.
- Operating Income: Increased 71% to $3.7 billion. This significant improvement was primarily due to a reduction in "Other operating charges" from $1.57 billion in Q1 2024 to $73 million in Q1 2025. The prior year included a $760 million impairment of the BodyArmor trademark and $765 million in contingent consideration remeasurement for fairlife.
- Cash Flow: Operating cash flow swung from a $528 million inflow in Q1 2024 to a $5.2 billion outflow in Q1 2025. This was primarily driven by a $6.1 billion final milestone payment for the fairlife acquisition made in March 2025.
- Volume: Worldwide unit case volume increased 2%, while concentrate sales volume increased 1%.
Guidance, Outlook, and Risks
- Outlook: Management expects foreign currency exchange rate fluctuations to have an unfavorable impact on full-year 2025 net operating revenues and operating income. The effective tax rate for 2025 is projected to be approximately 20.8%, excluding the potential impact of significant operating and nonoperating items.
- Capital Allocation: 2025 capital expenditures are expected to be approximately $2.2 billion. The Company plans to repurchase shares to offset dilution from employee stock-based compensation.
- IRS Tax Litigation: A material contingency exists regarding a dispute with the IRS over transfer pricing for tax years 2007–2009. The Tax Court ruled against the Company, resulting in a $6.0 billion liability (including interest) which the Company paid in September 2024 as a deposit pending appeal. The Company estimates a potential aggregate remaining incremental tax and interest liability of approximately $12 billion for tax years 2010–2024 if the Tax Court methodology is upheld and applied to subsequent years. The Company believes it is more likely than not to prevail on appeal.
- Environmental Matter: A lawsuit was filed in April 2025 by the U.S. Virgin Islands government regarding plastic packaging impacts, seeking injunctive relief and penalties.
Investor Verification Checklist
- fairlife Milestone Payment: Verify the impact of the $6.1 billion cash outflow on liquidity and the classification of the remaining contingent consideration liability.
- IRS Litigation Status: Monitor the appeal process in the U.S. Court of Appeals for the Eleventh Circuit and the potential $12 billion exposure for subsequent tax years.
- Foreign Currency Impact: Assess the sensitivity of future earnings to the strengthening U.S. dollar, which negatively impacted Q1 2025 results by 5% on revenue and 18% on operating income.
- BodyArmor Valuation: Review the remaining carrying value of the BodyArmor trademark ($3.4 billion) and the assumptions used in the impairment analysis following the Q1 2024 charge.
- Operating Cash Flow Volatility: Understand that Q1 2025 operating cash flow is not indicative of typical performance due to the one-time fairlife payment.